Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ILK | Q13418 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.35 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.35 |
| ▸ | FEN1 | P39748 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13884982 | 0.80 | SIGMAR1 (0.38) | ILKCNR2SMN1; SMN2NPC1LMNA | |
| SCHEMBL13869067 | 0.79 | CNR2 (0.41) | CNR2SIGMAR1CYP1A2 | |
| SCHEMBL21964546 | 0.77 | L3MBTL1 (0.43) | ILKSMN1; SMN2LMNAKEAP1 | |
| SCHEMBL17045428 | 0.76 | NPC1 (0.40) | SMN1; SMN2NPC1LMNATP53PKM | |
| SCHEMBL21964556 | 0.76 | MAP3K14 (0.39) | SMN1; SMN2NPC1LMNATP53PKM | |
| SCHEMBL22505581 | 0.73 | SIGMAR1 (0.40) | ILKLMNASIGMAR1KDM4E | |
| SCHEMBL17045382 | 0.73 | UBE2M (0.38) | SMN1; SMN2NPC1LMNATP53PKM | |
| SCHEMBL14662929 | 0.73 | SMN1; SMN2 (0.41) | ADORA2ASMN1; SMN2NPC1LMNATP53 | |
| SCHEMBL596225 | 0.73 | SMN1; SMN2 (0.41) | SMN1; SMN2NPC1LMNATP53PKM | |
| SCHEMBL17045327 | 0.72 | NPC1 (0.39) | SMN1; SMN2NPC1LMNATP53PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101365701-B | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB CO. (US) | 2011-11-30 | — | — | CN | disclosed |
| EP-1948664-B1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-06-08 | — | — | EP | disclosed |
| EP-1948664-B1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-06-08 | — | — | EP | disclosed |
| US-7514435-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-07 | — | — | US | disclosed |
| US-7514435-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-07 | — | — | US | disclosed |
| US-7514435-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-07 | — | — | US | disclosed |
| CN-101365701-A | Pyrrolotriazine kinase inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2009-02-11 | — | — | CN | disclosed |
| US-20070149534-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-28 | — | — | US | disclosed |
| US-20070149534-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-28 | — | — | US | disclosed |
| US-20070149534-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-28 | — | — | US | disclosed |
| WO-2007061882-A2 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149534-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | NTRK2, NTRK3, NTRK1 | ILK 1345/4885ADORA2A 2330/4885CNR2 1954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.